Aurobindo sees FY27 margins topping 21% after record ₹33,653 cr revenue year
Management guided for EBITDA margins above 21% in FY27, up from FY26, with Pen-G integration and European scale-up as the main levers. Biosimilars revenue now pushed to 2028.
— 5 earlier stories on Aurobindo Pharma Ltd. →What's new
- FY26 revenue hit a record ₹33,653 crore; management guided FY27 EBITDA margin above 21%.
- Biosimilars CDMO unit TheraNym now expects commercial revenue in 2028, not 2030 as previously indicated.
- Lannett acquisition in the US likely to close early in Q2 FY27 after regulatory delays.
Why this matters
The margin guidance is the real signal. Aurobindo is linking its Pen-G backward integration to the next leg of margin improvement, a play that hinges on the European business crossing €1 billion in scale. The biosimilars delay is a trade-off: management is pushing the timeline out, which suggests slower-than-expected commercialization of TheraNym, a unit that was supposed to diversify Aurobindo beyond generics.
What we're watching
- Whether the Lannett deal actually closes in Q2 FY27, after the regulatory delays.
- Pen-G external sales inflection — management flagged this as a margin driver, but execution details remain thin.
- FY27 quarterly margins to see if the 21%+ target holds through the year.
The full read
Aurobindo's FY26 revenue crossed ₹33,653 crore, a record. The more important number in the concall was the 21% EBITDA margin guide for FY27, which implies meaningful improvement from the prior year. The company is tying that to Pen-G backward integration and a European business that now sits at €1 billion. Both are structural, not one-offs, so the guide has some credibility if the integration stays on track. The biosimilars timeline, however, moved in the wrong direction. TheraNym's commercial revenue is now pushed to 2028, a year later than previously forecast, which is a clear signal that the unit is not yet a near-term growth driver. And the Lannett acquisition, which was supposed to strengthen Aurobindo's US portfolio, is still sitting in regulatory limbo. The company now expects it to close early in Q2 FY27, after delays. The concall had one clear message: Aurobindo is betting that scale and integration will lift margins. The open question is whether biosimilars and the US business can deliver the other half of the growth story.
Questions answered
- Why is Aurobindo guiding for EBITDA margins above 21% in FY27?
- The guidance is driven by operating leverage from Pen-G backward integration and the European business crossing €1 billion in scale. The FY26 results showed the scale was there; the FY27 margin guide says the next step is cost control and integration payoff.
- What happened to TheraNym's revenue timeline?
- Commercial revenue from TheraNym, the biosimilars CDMO unit, is now expected in 2028, not 2030 as previously forecast. The company did not specify what changed in the commercialization plan.
- Why was the Lannett acquisition delayed?
- The acquisition has faced regulatory delays, which is why it is now expected to close early in Q2 FY27 rather than sooner. The filing does not detail which regulator or what the hold-up was.
- How does Pen-G integration affect Aurobindo's margin profile?
- Aurobindo's Pen-G backward integration is a structural shift in its antibiotic supply chain. The company says this is now translating into operating leverage and an inflection in external sales, both of which are the core drivers behind the FY27 margin guidance above 21%.
Aurobindo Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on AUROPHARMA →- 22 May 2026 · 9:55 AM IST Aurobindo sees FY27 margins topping 21% after record ₹33,653 cr revenue year
- today Aurobindo gets second OAI plant in six months
- 22d ago Aurobindo’s FY26 audited results are a formality. Profit growth is 0.6%.
- 22d ago Aurobindo's TheraNym to build a drug plant for MSD, capex up to $175M
- 22d ago Aurobindo's FY26 revenue grows 5.6%, profit up 2%